$6.7M In Federal Grants Awarded to Develop Tech to Monitor, Treat Chronic Eye Diseases

Purdue researcher leads teams creating patent-pending smart contacts for glaucoma, neovascularization and dry eyes

Chronic Eye Diseases

Research teams led by a faculty member in Purdue University’s College of Engineering will use two grants from the National Eye Institute totaling $6.7 million to further develop specialized smart soft contact lenses that continuously monitor or treat chronic ocular diseases like glaucoma, corneal neovascularization and dry eye syndromes.

Chi Hwan Lee

Chi Hwan Lee leads the teams that are developing the patent-pending lenses, which can painlessly deliver therapeutic drugs or accurately measure intraocular pressure, or IOP. IOP is the only known modifiable risk factor for glaucoma.

Lee is the Leslie A. Geddes Associate Professor of Biomedical Engineering in Purdue’s Weldon School of Biomedical Engineering. He holds a joint appointment in the School of Mechanical Engineering and a courtesy appointment in the School of Materials Engineering.

Additional Researchers

Other researchers are Bryan Boudouris, Purdue’s associate vice president for research in strategic interdisciplinary research and the R. Norris and Eleanor Shreve Professor of Chemical Engineering in the Davidson School of Chemical Engineering; Shin Ae Park, assistant professor of ophthalmology in Purdue’s College of Veterinary Medicine; Pete Kollbaum, associate dean for research, director of the Borish Center for Ophthalmic Research and professor in Indiana University’s School of Optometry; and Dr. Yannis Paulus, associate professor of ophthalmology and visual sciences and biomedical engineering at Michigan Medicine.

Other Team Members

Team members also included Jinyuan Zhang, a former Purdue postdoctoral student in biomedical engineering and now a health technologies research and development engineer at Apple, and Yumin Dai, a graduate student in the School of Materials Engineering.

“Working on smart soft contact lenses allowed us to engage in top-tier interdisciplinary research, moving beyond theory to craft real-world solutions that aim to transform eye disease treatment,” Dai said. “We gained hands-on experience in biomedical engineering, materials science and clinical application, equipping us for future healthcare challenges. This project highlights our dedication to merging education with groundbreaking research, ensuring we’re prepared to make a real impact.”

The National Eye Institute is one of the National Institutes of Health; the funding comes from the NIH Research Project Grant Program, or R01.

The innovation

Lee specializes in StickTronics, which are stickerlike items that contain electronics or smart technology. He develops wearable biomedical devices that continuously monitor and manage chronic diseases or health conditions unobtrusively.

Some traditional wearable tonometers — devices that measure pressure inside the eyes — are equipped with an integrated circuit chip. This increases contact lens thickness and stiffness compared with a typical commercial soft contact lens, in many cases causing discomfort for patients. The research team’s version is different.

“To address this unmet need, we developed a unique class of smart soft contact lenses built upon various commercial brands of soft contact lenses for continuous 24-hour IOP monitoring and potentially treatment, even during sleep at home,” Lee said.

“Our smart soft contact lenses retain the intrinsic lens features of lens power, biocompatibility, softness, transparency, wettability, oxygen transmissibility and overnight wearability. Having all these features at the same time is crucial to the success of translating the smart soft contact lenses into ocular disease care, but these features are lacking in current devices.”

The NEI grants

Lee said the $6.7 million funding from the two NEI grants will further refine the smart soft contact lenses. Concurrently, clinical trials will be conducted in collaboration with Purdue’s College of Veterinary Medicine, the IU School of Optometry and Michigan Medicine to assess the lenses’ biosafety, usability, functionality, therapeutic effectiveness and durability.

“With the steadfast support from NEI, the successful completion of these projects will solidify our path toward introducing an innovative, closed-loop system for these smart contact lenses,” Lee said. “This system will enable simultaneous monitoring and drug delivery for a wide range of chronic ocular diseases.”

Lee disclosed the smart soft contact lenses innovation to the Purdue Innovates Office of Technology Commercialization, which has applied for a patent from the U.S. Patent and Trademark Office to protect the intellectual property.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”